SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
02 Mayo 2022 - 3:57PM
Business Wire
Kuznicki Law PLLC is investigating the proposed sale of Sierra
Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK).
Under the terms of the proposed transaction, shareholders of Sierra
will receive only $55.00 in cash for each share of Sierra that they
own.
If you would like to discuss your legal rights regarding the
proposed sale, you may, without obligation or cost to you, contact
us toll free at 833-938-0905, via email (dk@kclasslaw.com), or
visit https://kclasslaw.com/cases/ma/nasdaqgm-srra/ to learn
more.
Kuznicki Law PLLC is committed to ensuring that companies adhere
to responsible business practices and engage in good corporate
citizenship. The firm seeks recovery on behalf of investors who
incurred losses when false and/or misleading statements or the
omission of material information by a Company lead to artificial
inflation of the Company’s stock. Attorney advertising. Prior
results do not guarantee similar outcomes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005877/en/
Kuznicki Law PLLC Daniel Kuznicki, Esq. Email: dk@kclasslaw.com
Phone: (347) 696-1134 Cell: (347) 690-0692 Fax: (347) 348-0967
https://kclasslaw.com
Sierra Oncology (NASDAQ:SRRA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sierra Oncology (NASDAQ:SRRA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sierra Oncology Inc (NASDAQ): 0 recent articles
Más de Sierra Oncology, Inc. Artículos de Noticias